羅牛山(000735.SZ):擬以3954萬元收購潭牛飼料100%股權
格隆匯3月20日丨羅牛山(000735.SZ)公佈,公司擬向包括羅牛山集團有限公司在內的不超過35名特定對象發行股票,此次向特定對象發行股票數量不超過345,454,073股,未超過此次向特定對象發行股票前總股本的30%,擬募集資金總額不超過人民幣20.82億元,其中3954萬元用於收購海南(潭牛)文昌雞股份有限公司(簡稱“文昌雞股份”)持有的海南潭牛飼料有限公司(簡稱“潭牛飼料”或“標的公司”)100%股權。根據評估情況,並經雙方協商一致確定,標的股權的收購價格為3954萬元。
公司全資子公司海南羅牛山畜牧有限公司(簡稱“羅牛山畜牧”)已與文昌雞股份簽訂了《附條件生效的股權收購協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.